PTK6 and neoplasm: Treatment of breast tumor cells MDA-MB-231 and MDA-MB-453 with either compound leads to modest cell growth inhibition with similar potency despite their significant differences in PTK6 kinase inhibition (Fig 4A), suggesting that their off-target effects may account for the observed tumor growth inhibition.